Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs

Vaccine
Tjeerd G KimmanHester E de Melker

Abstract

Among all public health provisions national immunization programs (NIPs) are beyond doubt one of the most effective in reducing mortality, morbidity, and costs associated with major infectious diseases. To maintain their success, NIPs have to modernize in response to many new and old demands regarding efficacy, safety, availability of new vaccines, emerging and evolving pathogens, waning immunity, altered epidemiological situations, and the public's trust in the program. In this paper we present an evaluation model in the form of a checklist that may help in collecting relevant scientific information that is necessary for evaluation and decision making when considering changes in a NIP. Such a checklist points to relevant information on the vaccine-preventable disease, the pathogen causing it, the vaccine, and the cost-effectiveness ratio of the vaccine. However, the final judgment on a potential change in the NIP cannot be based on a simple algorithm, as the relevant information reflects factors of a very different kind and magnitude, to which different value judgements may be added, and which may have certain degrees of uncertainty. Because any change in the NIP may be accompanied by more or less unforeseen changes in the vac...Continue Reading

Citations

Dec 19, 2014·Avian Diseases·David M CastellanSubhash Morzaria
Apr 17, 2013·BMC Geriatrics·Renske EilersHester E de Melker
Feb 8, 2013·BMC Public Health·Hilde M van KeulenTheo W G M Paulussen
Jul 8, 2011·Health Policy and Planning·H E D BurchettA J Mills
Feb 12, 2013·International Journal of Nursing Studies·Richard G WamaiJavier Gordon Ogembo
Feb 16, 2010·Health Policy·Maggie BrysonAnn Jolly
Mar 2, 2010·Vaccine·Hans HouwelingUNKNOWN National Immunisation Programme Review Committee of the Health Council of the Netherlands
Nov 26, 2009·Vaccine·Siswanto Agus WilopoAbu Tholib
Aug 25, 2009·Vaccine·B Piso, C Wild
May 12, 2009·Vaccine·A VorstersP Van Damme
Aug 19, 2008·Vaccine·Naroesha JagessarNedret Emiroglu
Feb 13, 2007·Vaccine·B A M van der ZeijstG P J M van den Dobbelsteen
Feb 19, 2009·Journal of Advanced Nursing·Bernard DuvalFrance Lavoie
Jan 25, 2014·Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology·M E HoqueG Van Hal
Feb 14, 2012·Human Vaccines & Immunotherapeutics·Patricia BlankThomas D Szucs
Aug 4, 2016·BMC Public Health·Siriporn PooripussarakulSripen Tantivess
Nov 1, 2020·Vaccines·Jeroen LuytenPhilippe Beutels
Feb 16, 2021·Aging Clinical and Experimental Research·Regina Roller-WirnsbergerMaddalena Illario

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.